Multiple Myeloma Clinical Trial

Lenalidomide Adherence in Older Adults

Summary

To describe patterns of adherence and pilot baseline measures to investigate factors associated with lower adherence to lenalidomide in older adults with myeloma.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age ≥65
Receiving lenalidomide for treatment of multiple myeloma.
Anticipated to receive ongoing care at Siteman Cancer Center and its satellite sites
Able to read and understand English.
Able to understand and willing to sign an IRB-approved written informed consent document.

Exclusion Criteria:

Estimated life expectancy <6 months.
Anticipated duration of lenalidomide therapy <3 months.
Residing in a nursing facility where their medications are administered to them OR patient reports they do not self-administer their own medications.

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

17

Study ID:

NCT03779555

Recruitment Status:

Terminated

Sponsor:

Washington University School of Medicine

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Washington University School of Medicine
Saint Louis Missouri, 63110, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

17

Study ID:

NCT03779555

Recruitment Status:

Terminated

Sponsor:


Washington University School of Medicine

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider